Although anti‐VEGF therapy is beneficial in proliferative retinopathy (Mintz‐Hittner et al, 2011; Wells et al, 2015), the short‐lived effects of anti‐VEGF agents require frequent intervention (Rodrigues et al, 2009). Here, VEGFA is linked to retinal disorder.